Kmpharmaceutical KRX:225430KOSDAQ
케이엠제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked31since Sep 11
In Q2 2026, Kmpharmaceutical reported revenue of ₩3.8bn, up 18.4% year on year, and an operating loss of ₩585m. Kmpharmaceutical (케이엠제약) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals 4 quarters of losses Share pledge Delisting / halt risk Screener
Kmpharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩3.8bn | +18.4% | −₩585m margin −15.3% | −₩757m |
| Q1 2026 | ₩4.5bn | +9.5% | −₩659m margin −14.7% | −₩834m |
| Q4 2025 derived | ₩4.3bn | +26.4% | −₩851m margin −19.8% | −₩1.2bn |
| Q3 2025 | ₩4.4bn | +32.7% | −₩809m margin −18.5% | −₩1.0bn |
| Q2 2025 | ₩3.2bn | -2.2% | −₩721m margin −22.2% | −₩964m |
| Q1 2025 | ₩4.1bn | -8.7% | −₩542m margin −13.3% | −₩824m |
| Q4 2024 derived | ₩3.4bn | -2.0% | −₩470m margin −13.8% | −₩1.9bn |
| Q3 2024 | ₩3.3bn | -18.5% | −₩753m margin −22.8% | −₩950m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Kmpharmaceutical top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Kmpharmaceutical news Korean headlines
-
MajorCourt upholds injunction stay on KM Pharm delisting; court says move violates proportionality
1 more on this story · 1 outlets
- KM Pharm delisting hits brakes; court approves injunction stay뉴스락 · Oct 6 13:51
-
KM Pharm receives delisting notice and rises; SK Biopharm falls on FDA hold [Bio stocks on the move]
1 more on this story · 1 outlets